Cigna Group Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cigna Corporation on January 13, 2020. The filing serves as a Regulation FD disclosure regarding forward-looking statements and operational expectations to be presented by company officials, including CEO David M. Cordani, at the J.P. Morgan Healthcare Conference on January 13 and 14, 2020.
Key Financial Metrics and Operational Outlook
The filing does not provide historical financial results for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it outlines specific operational growth targets for the full year 2020:
- Total Medical Customer Growth: Expected increase of 150,000 to 250,000 customers over the year-end 2019 base.
- Individual Medicare Advantage Growth: Expected increase of 60,000 to 70,000 customers, representing 13% to 16% growth over year-end 2019.
- Health Services Adjusted Pharmacy Scripts: Expected range of 1.47 billion to 1.50 billion scripts for 2020.
- Pharmacy Script Growth: Represents an increase of 250 million to 280 million scripts (20% to 23% growth) over year-end 2019.
Material Changes and Strategic Drivers
The projected growth in pharmacy scripts includes volumes expected to be insourced from OptumRx and volumes associated with the first year of the Prime Therapeutics LLC collaboration. Additionally, the company anticipates organic growth of 25 million to 35 million adjusted pharmacy scripts. The filing notes that beginning in 2020, Cigna will no longer exclude contributions from Anthem, Inc. and Coventry Health Care Inc. from its adjusted measures, as the transition for these clients was substantially complete as of December 31, 2019. The impact from these transitioning clients on 2020 adjusted pharmacy scripts is expected to be de minimis.
Guidance, Risks, and Contingencies
Management intends to disclose these expectations during the J.P. Morgan Healthcare Conference. The filing includes a comprehensive Safe Harbor statement regarding forward-looking statements. Key risks and uncertainties cited include:
- Ability to achieve financial, strategic, and operational plans.
- Predicting and managing medical and pharmacy costs effectively.
- Adapting to changes in the regulatory and competitive environments.
- Integration of operations and realization of synergies from the merger with Express Scripts Holding Company.
- Government regulation, litigation outcomes, and participation in government-sponsored programs like Medicare.
- Macroeconomic conditions, including foreign currency movements and potential pandemics.
Full year 2019 financial results are scheduled to be released on February 6, 2020.
Investor Verification Checklist
- Verify the actual 2020 medical customer and pharmacy script volumes against the provided ranges (150k-250k customers; 1.47b-1.50b scripts) when Q4 2020 results are released.
- Monitor the integration progress and synergy realization of the Express Scripts merger.
- Review the February 6, 2020 press release for full year 2019 financial performance to establish a baseline for the 2020 growth targets.
- Assess the impact of regulatory changes on Medicare Advantage and pharmacy benefit management operations.